AYTU BIOPHARMA, INC. (AYTU) Total liabilities 2017–2026
AYTU BIOPHARMA, INC. (AYTU) total liabilities at each fiscal year-end, per SEC filings.
$69.7MFY2026 · since FY2017: $11.0M → $69.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $69.7M | -33.7% |
| FY2025 | $105.2M | +16.4% |
| FY2024 | $90.4M | -6.9% |
| FY2023 | $97.1M | +4.1% |
| FY2022 | $93.3M | -27.2% |
| FY2021 | $128.1M | +119.8% |
| FY2020 | $58.3M | +110.9% |
| FY2019 | $27.6M | +261.9% |
| FY2018 | $7.6M | -30.6% |
| FY2017 | $11.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More AYTU financial trends
AYTU RevenueAYTU Net incomeAYTU Net marginAYTU Gross profitAYTU Gross marginAYTU Operating incomeAYTU Operating marginAYTU Operating cash flowAYTU Free cash flowAYTU Capital expendituresAYTU Return on equityAYTU Stock buybacksAYTU Dividends paidAYTU Total assetsAYTU Shareholders’ equityAYTU overview →